title: The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
abstract: BACKGROUND
  The extent of the benefit of gefitinib in the treatment of advanced nonsmall-cell lung cancer (NSCLC) is till controversial, when compared with docetaxel. We performed this meta-analysis to compare the efficacy and toxicity of gefitinib with docetaxel for different patients with advanced NSCLC.
  
  
  METHODS
  We searched PubMed, Cochrane Library, and identified 5 randomized controlled clinical trials published within 2000-2013. After further full-text screening, 4 clinical trials were included in the final meta-analysis.
  
  
  RESULTS
  The outcomes of treatment efficacy included progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Comparing gefitinib to docetaxel for advanced NSCLC patients, the pooled hazard ratio (HR) of PFS was 0.91, (95% confidential index [CI] = 0.83-0.99), the pooled HR of OS was 1.02, (95% CI = 0.93-1.13), the pooled risk ratio of ORR was 1.57, (95% CI = 1.01-2.47).
  
  
  CONCLUSIONS
  Gefitinib was found to significantly improve patients' PFS and response rate compared with docetaxel. There is no difference of OS between gefitinib and docetaxel.
authors.forename: Y L
authors.initials: YL
authors.lastname: Zhao
authors.forename: S
authors.initials: S
authors.lastname: Han
authors.forename: R
authors.initials: R
authors.lastname: Pu
authors.affiliation: School of Pharmaceutical Science; International Research Center of Medicinal Administration, Peking University, Beijing 100191, China.
authors.forename: L W
authors.initials: LW
authors.lastname: Shi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000077143:Docetaxel; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011799:Quinazolines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D000077156:Gefitinib